Research graph
References from CD4+ T Cells Play Distinct Roles during the Priming versus Effector Phases of Immune Checkpoint Therapy–Dependent Tumor Elimination by CD8+ T Cells. Local targets link to admitted publications; unresolved targets remain external evidence.
Nivolumab versus everolimus in advanced renal-cell carcinoma
10.1056/nejmoa1510665 · 2015 · External reference
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
10.1056/nejmoa1507643 · 2015 · External reference
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
10.1056/nejmc1509660 · 2015 · External reference
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
10.1038/nature13988 · 2014 · External reference
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
10.1186/2051-1426-2-3 · 2014 · External reference
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
10.1038/nature19330 · 2016 · External reference
Fundamental mechanisms of immune checkpoint blockade therapy
10.1158/2159-8290.cd-18-0367 · 2018 · External reference
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
10.1126/science.aaf0683 · 2017 · External reference
MHC-II neoantigens shape tumour immunity and response to immunotherapy
10.1038/s41586-019-1671-8 · 2019 · External reference
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
10.1038/s41590-019-0312-6 · 2019 · External reference
Defining T cell states associated with response to checkpoint immunotherapy in melanoma
10.1016/j.cell.2018.10.038 · 2018 · External reference
Molecular and cellular insights into T cell exhaustion
10.1038/nri3862 · 2015 · External reference
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
10.1126/science.aaf2807 · 2016 · External reference
cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity
10.1038/s41586-020-2611-3 · 2020 · External reference
CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer
10.1016/j.immuni.2019.10.009 · 2019 · External reference
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
10.1016/j.ccell.2024.05.025 · 2024 · External reference
Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma
10.1038/s41591-023-02345-0 · 2023 · External reference
CD27 agonism plus PD-1 blockade recapitulates CD4+ T-cell help in therapeutic anticancer vaccination
10.1158/0008-5472.can-15-3130 · 2016 · External reference
CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness
10.1016/j.immuni.2017.10.009 · 2017 · External reference
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
10.1038/31002 · 1998 · External reference
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
10.1038/30989 · 1998 · External reference
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
10.1038/30996 · 1998 · External reference
T-helper-1-cell cytokines drive cancer into senescence
10.1038/nature11824 · 2013 · External reference
TNFR1 signaling and IFN-γ signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis
10.1016/j.ccr.2008.04.001 · 2008 · External reference
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells
10.1084/jem.161.5.1122 · 1985 · External reference
Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo
10.4049/jimmunol.154.9.4613 · 1995 · External reference
Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer
10.1016/j.cell.2020.05.017 · 2020 · External reference
Tumor killing by CD4+ T cells is mediated via induction of inducible nitric oxide synthase-dependent macrophage cytotoxicity
10.3389/fimmu.2018.01684 · 2018 · External reference
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
10.1084/jem.20091918 · 2010 · External reference
Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors
10.1038/s41590-023-01543-9 · 2023 · External reference
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
10.1038/s41586-023-06199-x · 2023 · External reference
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
10.1056/nejmoa0800251 · 2008 · External reference
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity
10.1016/j.ccell.2025.07.001 · 2025 · External reference
CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes
10.1158/0008-5472.can-10-1322 · 2010 · External reference
High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy
10.1016/j.cell.2018.11.003 · 2018 · External reference
Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape
10.1158/2326-6066.cir-16-0391 · 2017 · External reference
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
10.1038/35074122 · 2001 · External reference
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
10.1038/nature10755 · 2012 · External reference
Improvement of tumor neoantigen detection by high field asymmetric waveform ion mobility mass spectrometry
10.1158/2326-6066.cir-23-0900 · 2024 · External reference
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
10.1038/s41586-024-07752-y · 2024 · External reference
Sequencing and cloning of antigen-specific antibodies from mouse memory B cells
10.1038/nprot.2016.102 · 2016 · External reference
A potently neutralizing antibody protects mice against SARS-CoV-2 infection
10.4049/jimmunol.2000583 · 2020 · External reference
TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE
10.1084/jem.20052438 · 2006 · External reference
Cloning and expression of murine Ig genes from single B cells
10.1016/j.jim.2009.08.009 · 2009 · External reference
Refined protocol for generating monoclonal antibodies from single human and murine B cells
10.1016/j.jim.2016.09.001 · 2016 · External reference
Longitudinal analysis of the human B cell response to ebola virus infection
10.1016/j.cell.2019.04.036 · 2019 · External reference
A vaccine strategy that protects against genital herpes by establishing local memory T cells
10.1038/nature11522 · 2012 · External reference
CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help
10.1038/nature08511 · 2009 · External reference
Dynamic programing of CD8+ T cell trafficking after live viral immunization
10.1016/j.immuni.2006.06.019 · 2006 · External reference
Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720
10.1016/0960-894x(95)00127-f · 1995 · External reference
FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression
10.1016/s0041-1345(00)02126-6 · 2001 · External reference
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
10.1016/j.celrep.2024.114141 · 2024 · External reference
Systemic immunity is required for effective cancer immunotherapy
10.1016/j.cell.2016.12.022 · 2017 · External reference
Efficient generation of monoclonal antibodies against peptide in the context of MHCII using magnetic enrichment
10.1038/ncomms11804 · 2016 · External reference
Mechanisms of CD40-dependent cDC1 licensing beyond costimulation
10.1038/s41590-022-01324-w · 2022 · External reference
Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection
10.4049/jimmunol.155.12.5690 · 1995 · External reference
IL-21 is required to control chronic viral infection
10.1126/science.1174182 · 2009 · External reference
Lymph-node-derived stem-like but not tumor-tissue-resident CD8+ T cells fuel anticancer immunity
10.1038/s41590-025-02219-2 · 2025 · External reference
The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes
10.1016/j.ccell.2020.09.001 · 2020 · External reference
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy
10.1172/jci.insight.124507 · 2018 · External reference
